Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 10/21/2017 4:15:32 PM - Followers: 147 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#4884  Sticky Note AUPH: Now that Ph3 for LN is underway Lunacy aka John Galt 07/19/17 06:05:27 PM
#5816   Moose, this is the highest price I bought Jesspro 10/21/17 04:15:32 PM
#5815   " I bought at the close today for moosedogger 10/21/17 08:29:48 AM
#5814   I agree. Jesspro 10/20/17 09:04:53 PM
#5813   Indeed L-M biotech_researcher 10/20/17 08:24:00 PM
#5812   Glickman does indeed own shares in AUPH. And biotech_researcher 10/20/17 08:22:21 PM
#5811   fewer, not less LadiesMan 10/20/17 06:44:54 PM
#5810   Jess I’m willing to bet that he does Maciste 10/20/17 06:31:09 PM
#5809   “One year from now we'll have impending data biotech_researcher 10/20/17 06:16:42 PM
#5808   Really classic BR. Fundamentals remain the same and Jesspro 10/20/17 05:36:06 PM
#5807   Hate to say it but this was Glickman's tiv111 10/20/17 05:32:54 PM
#5806   So by your logic, a week ago when SvsB 10/20/17 05:27:59 PM
#5805   One year from now we'll have impending data nferna 10/20/17 03:52:28 PM
#5804   Why is it an annual thing. It's not puravida 10/20/17 03:41:34 PM
#5803   Indeed!! All institutions have sold and long Maciste 10/20/17 02:00:07 PM
#5802   HEAVY volume on this big (5%-6%) move down. biotech_researcher 10/20/17 01:51:35 PM
#5801   Negative, sell PUTS. biotech_researcher 10/20/17 01:39:54 PM
#5800   Relax BR. Shortly we may get into moosedogger 10/20/17 12:54:21 PM
#5799   What I find disheartening is they are crushing biotech_researcher 10/20/17 12:39:34 PM
#5798   Classic BR puravida 10/20/17 10:53:58 AM
#5797   Glicky must have under delivered as AUPH is zzaatt 10/20/17 10:39:59 AM
#5796   Indeed! Speculative? cervelo 10/20/17 09:56:55 AM
#5795   Indeed! Maciste 10/20/17 09:51:55 AM
#5794   Glicky must have under delivered as AUPH is plunging... biotech_researcher 10/20/17 09:50:46 AM
#5793   I rolled all my money into Auph from Ariad! Hotrodder1 10/20/17 08:24:31 AM
#5792   Aurinia to Expand Renal Franchise with Novel Indications BigWorm129 10/20/17 08:14:01 AM
#5791   I heard Duggan likes an omelet bar puravida 10/20/17 06:46:27 AM
#5790   Ham & eggs, Lox & bagels- NYC venue moosedogger 10/20/17 02:54:29 AM
#5789   Wow Hotrod, that’s a lot of dough. Boy, Jesspro 10/19/17 10:58:42 PM
#5788   PS, and I don’t get an invite! Hotrodder1 10/19/17 09:18:46 PM
#5787   I’m in over 50 thousand shares. I’ll wait! Hotrodder1 10/19/17 09:17:48 PM
#5786   We could be sideways for a while depending Jesspro 10/19/17 04:55:39 PM
#5785   Glicky better have egg sandwiches tomorrow morning and biotech_researcher 10/19/17 03:40:43 PM
#5784   next week after options expiration. Of course significant tiv111 10/19/17 03:22:42 PM
#5783   any speculation when this company might go up cervelo 10/19/17 02:44:40 PM
#5782   Jess, his last post was in July 2017 biotech_researcher 10/19/17 12:07:19 PM
#5781   The same handle BR. Look for his latest post. Jesspro 10/19/17 11:55:13 AM
#5780   What is 2da’s new moniker? biotech_researcher 10/19/17 09:51:34 AM
#5779   all we need now is 2DA staying up puravida 10/19/17 08:03:49 AM
#5778   Yes, it feels like it except that we Jesspro 10/18/17 11:37:12 PM
#5777   It sure does feel like it.. biotech_researcher 10/18/17 08:32:48 PM
#5776   Feels like it, doesn't it? nsomniyak 10/18/17 08:30:20 PM
#5775   Hahaha. This is the ariad board all over puravida 10/18/17 07:29:47 PM
#5774   Down over a dollar... Thanks! Your DD is extraordinary. zzaatt 10/18/17 07:14:44 PM
#5773   Just think, this touched $7.60 a few short biotech_researcher 10/18/17 04:04:20 PM
#5772   That's pure SPECULATION...........indeed cervelo 10/18/17 12:27:04 PM
#5771   Todays action is key, vital, critical, crucial, pivotal, SvsB 10/18/17 12:25:48 PM
#5770   Indeed too! Jesspro 10/18/17 10:27:51 AM
#5769   Indeed! Maciste 10/18/17 10:26:16 AM
#5768   Looks like they are going after it again. biotech_researcher 10/18/17 09:58:48 AM
#5767   Interesting news item regarding AstraZeneca/Roche, 3 others. ThePromise247 10/17/17 01:14:19 PM